Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

1) Two-year carcinogenicity study in rats with read-across chemical Mesna (CAS 19767-45-4) (Tacchi et al., 1984); Not carcinogenic, NOAEL 350 mg/kg bw.
2) Prediction using TOXTREE (v.2.5.0), Chemservice S.A., 2011

Key value for chemical safety assessment

Carcinogenicity: via oral route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: oral
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: The OECD QSAR Toolbox, is a harmonized system for OSAR application and grouping chemicals into categories, which OECD principles are met.
Qualifier:
according to guideline
Guideline:
OECD Guideline 451 (Carcinogenicity Studies)
Deviations:
not specified
Principles of method if other than guideline:
92 male Sprague-Dawley rats, 8 weeks old, were divided into two groups. Group A received 70 mg/kg N-nitroso-N-butyl-N-(4-hydroxybutyl)amine (BBNOH) twice a week by gavage, whereas to Group B, BBNOH was administered at the same dose level together with 350 mg/kg Mesna given 5 times a week in drinking water. Two control groups of 40 animals each were given Mesna alone or were totally untreated.
GLP compliance:
not specified
Species:
rat
Strain:
Sprague-Dawley
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Süddeutsche Versuchstierfarm, Tuttlingen, F.R.G
- Age at study initiation: 8 weeks
- Weight at study initiation: no data (the weight was checked regularly during the entire period of the treatment).
- Fasting period before study: no data
- Housing: 2 per cage
- Diet (e.g. ad libitum): Altrominm pellets diet; ad libitum
- Water (e.g. ad libitum): tap water; ad libitum
- Acclimation period: no data

ENVIRONMENTAL CONDITIONS
No data
Route of administration:
oral: drinking water
Vehicle:
water
Details on exposure:
PREPARATION OF DOSING SOLUTIONS: 20 mL Mesna solutions were given to rats 5 days a week.

Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
39 weeks
Frequency of treatment:
5 times a week
Post exposure period:
No data
Remarks:
Doses / Concentrations:
350 mg/kg bw
Basis:
nominal in water
No. of animals per sex per dose:
40
Control animals:
yes, concurrent no treatment
Details on study design:
- Dose selection rationale: The high dose of Mesna was chosen in order to provide an excess amount that could interfere with the metabolites of BBNOH in the urinary bladder.
Positive control:
N-nitroso-N-butyl-N-(4-hydroxybutyl)amine (BBNOH) alone.
Observations and examinations performed and frequency:
The body weight was checked regularly during the entire period of the treatment.
Sacrifice and pathology:
At the end of the treatment animals were observed for life, with the exception of a few that were killed when moribund. After dissection, urinary bladders and all other organs showing macroscopical alterations were collected for histological examination.
Statistics:
Kaplan-Meier method.
Clinical signs:
no effects observed
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Water consumption and compound intake (if drinking water study):
no effects observed
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
no effects observed
Description (incidence and severity):
Negative
Details on results:
CLINICAL SIGNS AND MORTALITY
No significant differences were observed in the animals of the 4 experimental groups from a general point of view. Control animals did not show any pathological alteration at the end of the experiment. There were no signs of toxicity in the animals that received Mesna alone. A statistically significant increase of the lifespan of the Mesna treated animals was observed (P< 0.05).

BODY WEIGHT AND WEIGHT GAIN
Administration of Mesna did not have a significant effect on the weight; an increase in body weight was observed at the beginning of the treatment, up to the eighteenth week, followed by a slight decrease and a steady phase at the end of the experiment. Values ranged between 300 g and 500 g for all experimental groups.

WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
Mesna solutions were completely consumed within 24 h from the time of administration. The total Mesna consumption was 63.35 g/kg.

GROSS PATHOLOGY
No findings.

HISTOPATHOLOGY: NON-NEOPLASTIC
No findings.

HISTOPATHOLOGY: NEOPLASTIC (if applicable)
No findings.
Relevance of carcinogenic effects / potential:
The carcinogenicity study conducted with the structural analogue Mesna provides an information on toxicity potential of the substance of interest sodium 3-mercaptosulfonate after a prolonged exposure and can serve as additional information for the assessment of its genotoxicity potential.
Dose descriptor:
NOAEL
Effect level:
350 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: see 'Remark'
Remarks on result:
other: Effect type: carcinogenicity (migrated information)





The prediction was based on dataset comprised from the following descriptors: "Summary carcinogenicity"
Estimation method: Takes highest mode value from the 5 nearest neighbours
Domain logical expression:Result: Out of Domain

("a" and ("b" and "c" ) )

Domain logical expression index: "a"

Referential boundary: The target chemical should be classified as Sulfonic acid AND Thioalcohol by Organic functional groups

Domain logical expression index: "b"

Parametric boundary:The target chemical should have a value of log Kow which is >= -4.09

Domain logical expression index: "c"

Parametric boundary:The target chemical should have a value of log Kow which is <= -4.09

Conclusions:
Mesna was not carcinogenic in a two-year carcinogenicity study in rats. 350 mg/kg bw, which rats received daily during the exposure period of 39 weeks, can be considered as NOAEL since no clinical signs of toxicity and no findings of necropsy were noted in treated animals.
Executive summary:

Mesna is known as a cytoprotective agent that helps to prevent haemorrhagic cystitis caused by a widely used class of antineoplastic drugs, comprising cyclophosphamide, ifosfamide, and trofosfamide (Tacchi et al., 1984). A direct chemical interaction between Mesna and the active metabolites of antineoplastic drugs is supposed to be involved in the protective effects on the urinary bladder. In this respect, the influence of Mesna on urinary bladder cancer induced by N-nitroso-N-butyl-N-(4 hydroxybutyl)amine (BBNOH) was studied in male Sprague-Dawley rats.
The treatment consisted of the administration of BBNOH alone per gavage, BBNOH with Mesna, Mesna alone and untreated control. The health effects in treated animals receiving Mesna alone is relevant for this endpoint. The group of 40 male animals (8-week old) received 350 mg/kg bw (total Mesna consumption was 63 g/kg bw (mean for all animals)) in drinking water over a period of 39 weeks. The rats received daily the dose in 20 mL water solution 5 days a week. Health condition of the animals and their body weights were checked regularly during the entire period of the treatment. At the end of the treatment animals were killed and dissected and urinary bladders and all other organs showing macroscopical alterations were collected for histological examination.
No significant differences were observed in the animals of the 4 experimental groups from a general point of view. Mesna solutions were completely consumed within 24 h from the time of administration. Administration of Mesna did not have a significant effect on the weight; an increase in body weight was observed at the beginning of the treatment, up to the eighteenth week, followed by a slight decrease and a steady phase at the end of the experiment. Values ranged between 300 g and 500 g for all experimental groups. Control animals (untreated and receiving Mesna alone) did not show any pathological alteration at the end of the experiment and there were no signs of toxicity. A statistically significant increase of the lifespan of the Mesna treated animals was observed (P< 0.05).
There were no findings at necropsy.
As no toxicological findings were observed in animals treated with Mesna alone, 350 mg/kg bw can be considered as chronic NOAEL.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
350 mg/kg bw/day
Study duration:
chronic
Species:
rat
Quality of whole database:
Read-across chemical.

Justification for classification or non-classification

Based on the negative result of the carcinogenicity study conducted with the nearest analogue mesna, the target substance MPS , sodium 3 -mercaptopropanesulfonate does not need to be classified and labelled as carcinogenic according to Regulation 1272/2008/EC (CLP).

Additional information

A structurally similar chemical sodium-2-mercaptoethanesulfonate (mesna) (CAS 19767 -45 -4) was identified with the aid of the OECD QSAR Toolbox (v.3.0) using "Organic functional groups" as grouping method. A carcinogenicity study mentioned in the Toolbox was freely available via public databases. Mesna is a structurally similar analogue to the target chemical, has the same functional groups (thiol and sulfonic), similar reactivity to biomolecules (the same mechanism of action), similar physico-chemical properties (water solubility and logPow), and therefore expected to behave similarly in absorption, distribution throughout the body, yielding similar metabolites.

Mesna is known as a cytoprotective agent that helps to prevent haemorrhagic cystitis caused by a widely used class of antineoplastic drugs, comprising cyclophosphamide, ifosfamide, and trofosfamide (Tacchi et al., 1984). A direct chemical interaction between mesna and the active metabolites of antineoplastic drugs is supposed to be involved in the protective effects on the urinary bladder. In this respect, the influence of mesna on urinary bladder cancer induced by N-nitroso-N-butyl-N-(4 hydroxybutyl)amine (BBNOH) was studied in male Sprague-Dawley rats.
The treatment consisted of the administration of BBNOH alone per gavage, BBNOH with mesna, mesna alone and untreated control. The health effects in treated animals receiving mesna alone are relevant for this endpoint. The group of 40 male animals (8-week old) received 350 mg/kg bw (total mesna consumption was 63 g/kg bw (mean for all animals)) in drinking water over a period of 39 weeks. The rats received daily the dose in 20 mL water solution 5 days a week. Health condition of the animals and their body weights were checked regularly during the entire period of the treatment. At the end of the treatment animals were killed and dissected and urinary bladders and all other organs showing macroscopical alterations were collected for histological examination.
No significant differences were observed in the animals of the 4 experimental groups from a general point of view. Mesna solutions were completely consumed within 24 h from the time of administration. Administration of mesna did not have a significant effect on the weight; an increase in body weight was observed at the beginning of the treatment, up to the eighteenth week, followed by a slight decrease and a steady phase at the end of the experiment. Values ranged between 300 g and 500 g for all experimental groups. Control animals (untreated and receiving mesna alone) did not show any pathological alteration at the end of the experiment and there were no signs of toxicity. A statistically significant increase of the lifespan of the mesna treated animals was observed (P< 0.05).
There were no findings at necropsy.
As no toxicological findings were observed in animals treated with mesna alone, 350 mg/kg bw can be considered as chronic NOAEL.

Prediction using Toxtree (v.2.5.0):

The carcinogenic toxicity potential of 1-Propanesulfonic acid, 3-mercapto-, monosodium salt was assessed using the Toxtree (version 2.5.0.) modelling tool. Toxtree was developed by IDEA Consult Ltd (Sofia, Bulgaria) and is approved and recommended by the EU Joint Research Center in Ispra (Italy) (LINK:http://ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?c=TOXTREE). According to the modelling results of Toxtree, no structural alerts were identified for genotoxic and non-genotoxic carcinogenicity of 1-Propanesulfonic acid, 3-mercapto-, monosodium salt. Therefore the substance does not bear the potential for carcinogenicity.

 


Justification for selection of carcinogenicity via oral route endpoint:
The test result originates from an old study published (1984) conducted with a nearest analogue to the target chemical. The publication has been found via OECD QSAR Toolbox (v.3.0) by searching for structurally similar chemicals with long-term toxicity data. The publication is well documented and meets basic scientific principles. The justification on suitability of the analogue substance for the read-across purposes is presented in the section 7.5 (Endpoint summary on repeated dose toxicity) or in the chapter 5.6.3. of CSR.